Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Director · Chief Executive Officer | September 11, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROCRINE BIOSCIENCES INC
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 157,266 |
Reported balance
After 2026-09-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-11 · Grant · Acquired 6,275 · Balance 157,266 F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. F2: Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 153,880 |
Reported balance
After 2026-09-11 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-11 · Tax withholding · Disposed 3,386 · Balance 153,880 F3: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. |
| Common StockSEC Table I · non-derivative | Direct | 155,722 |
Reported balance
After 2026-09-11 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-09-11 · Grant · Acquired 1,842 · Balance 155,722 F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 154,728 |
Reported balance
After 2026-09-11 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-09-11 · Tax withholding · Disposed 994 · Balance 154,728 F3: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
F2: Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
F3: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 15, 2026 21:05 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 994 | $156.22 | $155,282.68 |
DisclosureSEC source: 0001567160-26-000009 · wk-form4_1789506302.xml · nonDerivative · entry 4 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,728 F3 · kind: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 21:05 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantCommon Stock | 1,842 | $0.00 | $0.00 |
DisclosureSEC source: 0001567160-26-000009 · wk-form4_1789506302.xml · nonDerivative · entry 3 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,722 F1 · kind: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 21:05 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 3,386 | $156.22 | $528,960.92 |
DisclosureSEC source: 0001567160-26-000009 · wk-form4_1789506302.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,880 F3 · kind: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 21:05 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantCommon Stock | 6,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001567160-26-000009 · wk-form4_1789506302.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,266 F1 · kind: The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026. F2 · balance_after: Includes an aggregate of 176 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 20,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · derivative · entry 13 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,142 Underlying: Common Stock · 20,142 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F8 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. F8 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 114,830 | $0.00 Strike: $124.12 | $0.00 |
DisclosureSEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · derivative · entry 12 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,830 Underlying: Common Stock · 114,830 shares Expires 2036-02-13 F7 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 2,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · derivative · entry 11 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,566 Underlying: Common Stock · 2,566 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,566 shares on February 13, 2024, vested as to 2,566 shares on February 13, 2025, vested as to 2,566 shares on February 13, 2026, and will vest as to 2,566 shares on February 13, 2027, subject to the terms and conditions of the award. F6 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,566 shares on February 13, 2024, vested as to 2,566 shares on February 13, 2025, vested as to 2,566 shares on February 13, 2026, and will vest as to 2,566 shares on February 13, 2027, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 2,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · derivative · entry 10 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,484 Underlying: Common Stock · 2,241 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,241 shares on February 13, 2025, vested as to 2,241 shares on February 13, 2026, and will vest as to 2,242 shares on February 13, 2027, and 2,242 shares on February 13, 2028, subject to the terms and conditions of the award. F5 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,241 shares on February 13, 2025, vested as to 2,241 shares on February 13, 2026, and will vest as to 2,242 shares on February 13, 2027, and 2,242 shares on February 13, 2028, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 5,378 | $124.12 | $667,517.36 |
DisclosureSEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · nonDerivative · entry 8 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,815 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantCommon Stock | 9,968 | $0.00 | $0.00 |
DisclosureSEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · nonDerivative · entry 7 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,193 F2 · shares: On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 1,385 | $124.12 | $171,906.20 |
DisclosureSEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · nonDerivative · entry 6 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,225 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · nonDerivative · entry 5 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 1,210 | $124.12 | $150,185.20 |
DisclosureSEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · nonDerivative · entry 4 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,044 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 13, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · nonDerivative · entry 3 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 4,907 | $0.00 | $0.00 |
DisclosureSEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · derivative · entry 9 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,721 Underlying: Common Stock · 4,907 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 4,907 shares on February 12, 2026, and will vest as to 4,907 shares on February 12, 2027, 4,907 shares on February 12, 2028, and 4,907 shares on February 12, 2029, subject to the terms and conditions of the award. F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 4,907 shares on February 12, 2026, and will vest as to 4,907 shares on February 12, 2027, 4,907 shares on February 12, 2028, and 4,907 shares on February 12, 2029, subject to the terms and conditions of the award. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 2,648 | $123.10 | $325,968.80 |
DisclosureSEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,013 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 22:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 4,907 | $0.00 | $0.00 |
DisclosureSEC source: 0001567160-26-000007 · wk-form4_1771368497.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 2,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001567160-26-000005 · wk-form4_1770159832.xml · derivative · entry 3 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,927 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,926 shares on January 31, 2023, vested as to 2,926 shares on January 31, 2024, vested as to 2,927 shares on January 31, 2025, and vested as to 2,927 shares on January 31, 2026, subject to the terms and conditions of the award. F3 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,926 shares on January 31, 2023, vested as to 2,926 shares on January 31, 2024, vested as to 2,927 shares on January 31, 2025, and vested as to 2,927 shares on January 31, 2026, subject to the terms and conditions of the award. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Tax withholdingCommon Stock | 1,580 | $136.06 | $214,974.80 |
DisclosureSEC source: 0001567160-26-000005 · wk-form4_1770159832.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,754 F1 · shares: Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 23:03 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001567160-26-000005 · wk-form4_1770159832.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2026 Filed Jan 20, 2026 23:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionIncentive Stock Option · Derivative | 1,812 | $0.00 Strike: $35.99 | $0.00 |
DisclosureSEC source: 0001567160-26-000002 · wk-form4_1768953377.xml · derivative · entry 6 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,812 shares Expires 2026-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning on March 5, 2016. These options were due to expire on February 5, 2026. Read SEC document |
| January 16, 2026 Filed Jan 20, 2026 23:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 34,588 | $0.00 Strike: $35.99 | $0.00 |
DisclosureSEC source: 0001567160-26-000002 · wk-form4_1768953377.xml · derivative · entry 5 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,588 shares Expires 2026-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning on March 5, 2016. These options were due to expire on February 5, 2026. Read SEC document |
| January 16, 2026 Filed Jan 20, 2026 23:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,812 | $132.71 | $240,478.31 |
DisclosureSEC source: 0001567160-26-000002 · wk-form4_1768953377.xml · nonDerivative · entry 4 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,407 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.49 to $133.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range Read SEC document |
| January 16, 2026 Filed Jan 20, 2026 23:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,812 | $35.99 | $65,213.88 |
DisclosureSEC source: 0001567160-26-000002 · wk-form4_1768953377.xml · nonDerivative · entry 3 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2026 Filed Jan 20, 2026 23:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 34,588 | $132.70 | $4,589,979.79 |
DisclosureSEC source: 0001567160-26-000002 · wk-form4_1768953377.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,407 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.42 to $133.98. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range Read SEC document |
| January 16, 2026 Filed Jan 20, 2026 23:56 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 34,588 | $35.99 | $1,244,822.12 |
DisclosureSEC source: 0001567160-26-000002 · wk-form4_1768953377.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 174,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 01:18 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 300 | $141.97 | $42,591.00 |
DisclosureSEC source: 0001567160-25-000008 · wk-form4_1762305492.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,407 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| November 01, 2025 Filed Nov 5, 2025 01:18 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 613 | $0.00 | $0.00 |
DisclosureSEC source: 0001567160-25-000008 · wk-form4_1762305492.xml · derivative · entry 3 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,842 Underlying: Common Stock · 613 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on November 1, 2024. In accordance with the terms of the RSU, the award vested as to 613 shares on November 1, 2025, and will vest as to 614 shares on November 1, 2026, 614 shares on November 1, 2027, and 614 shares on November 1, 2028, subject to the terms and conditions of the award. F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on November 1, 2024. In accordance with the terms of the RSU, the award vested as to 613 shares on November 1, 2025, and will vest as to 614 shares on November 1, 2026, 614 shares on November 1, 2027, and 614 shares on November 1, 2028, subject to the terms and conditions of the award. Read SEC document |
| November 01, 2025 Filed Nov 5, 2025 01:18 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 613 | $0.00 | $0.00 |
DisclosureSEC source: 0001567160-25-000008 · wk-form4_1762305492.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 200 shares purchased on February 28, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:20 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 2,241 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000063 · wk-form4_1739575198.xml · derivative · entry 8 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,725 Underlying: Common Stock · 2,241 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F9 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,241 shares on February 13, 2025, and will vest as to 2,241 shares on February 13, 2026, 2,242 shares on February 13, 2027, and 2,242 shares on February 13, 2028, subject to the terms and conditions of the award. F9 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 2,241 shares on February 13, 2025, and will vest as to 2,241 shares on February 13, 2026, 2,242 shares on February 13, 2027, and 2,242 shares on February 13, 2028, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:20 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 2,566 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000063 · wk-form4_1739575198.xml · derivative · entry 7 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,132 Underlying: Common Stock · 2,566 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F8 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,566 shares on February 13, 2024, vested as to 2,566 shares on February 13, 2025, and will vest as to 2,566 shares on February 13, 2026, and 2,566 shares on February 13, 2027, subject to the terms and conditions of the award. F8 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,566 shares on February 13, 2024, vested as to 2,566 shares on February 13, 2025, and will vest as to 2,566 shares on February 13, 2026, and 2,566 shares on February 13, 2027, subject to the terms and conditions of the award. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:20 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,206 | $116.86 | $140,933.88 |
DisclosureSEC source: 0000914475-25-000063 · wk-form4_1739575198.xml · nonDerivative · entry 4 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,907 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.04 to $117.53. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:20 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,241 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000063 · wk-form4_1739575198.xml · nonDerivative · entry 3 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,113 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:20 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,352 | $116.84 | $157,974.17 |
DisclosureSEC source: 0000914475-25-000063 · wk-form4_1739575198.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,872 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.02 to $118.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 23:20 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,566 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000063 · wk-form4_1739575198.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:20 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestricted Stock Unit · Derivative | 19,628 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000063 · wk-form4_1739575198.xml · derivative · entry 6 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,628 Underlying: Common Stock · 19,628 shares Expires not disclosed F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029. F7 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 12, 2026, February 12, 2027, February 12, 2028, and February 12, 2029. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 23:20 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 104,736 | $0.00 Strike: $117.18 | $0.00 |
DisclosureSEC source: 0000914475-25-000063 · wk-form4_1739575198.xml · derivative · entry 5 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,736 Underlying: Common Stock · 104,736 shares Expires 2035-02-12 F5 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 23:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 980 | $118.39 | $116,020.34 |
DisclosureSEC source: 0000914475-25-000049 · wk-form4_1739404081.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,658 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 10, 2021. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $116.08 to $123.57. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 23:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 1,860 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000049 · wk-form4_1739404081.xml · derivative · entry 3 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,860 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on February 8, 2021. In accordance with the terms of the RSU, the award vested as to 1,859 shares on February 8, 2022, vested as to 1,860 shares on February 8, 2023, vested as to 1,860 shares on February 8, 2024, and vested as to 1,860 shares on February 8, 2025, subject to the terms and conditions of the award. F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on February 8, 2021. In accordance with the terms of the RSU, the award vested as to 1,859 shares on February 8, 2022, vested as to 1,860 shares on February 8, 2023, vested as to 1,860 shares on February 8, 2024, and vested as to 1,860 shares on February 8, 2025, subject to the terms and conditions of the award. Read SEC document |
| February 08, 2025 Filed Feb 12, 2025 23:48 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 1,860 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000049 · wk-form4_1739404081.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 2,927 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000025 · wk-form4_1738709227.xml · derivative · entry 3 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,927 Underlying: Common Stock · 2,927 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,926 shares on January 31, 2023, vested as to 2,926 shares on January 31, 2024, vested as to 2,927 shares on January 31, 2025, and will vest as to 2,927 shares on January 31, 2026, subject to the terms and conditions of the award. F4 · derivative.expiration_date: This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 2,926 shares on January 31, 2023, vested as to 2,926 shares on January 31, 2024, vested as to 2,927 shares on January 31, 2025, and will vest as to 2,927 shares on January 31, 2026, subject to the terms and conditions of the award. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 1,541 | $152.87 | $235,577.45 |
DisclosureSEC source: 0000914475-25-000025 · wk-form4_1738709227.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,778 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2022. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.94 to $153.59. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:47 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 2,927 | $0.00 | $0.00 |
DisclosureSEC source: 0000914475-25-000025 · wk-form4_1738709227.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138,319 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:32 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 60,188 | $0.00 Strike: $32.99 | $0.00 |
DisclosureSEC source: 0000914475-25-000004 · wk-form4_1737149514.xml · derivative · entry 6 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,188 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted February 3, 2015 and vested in 48 equal monthly installments beginning on March 3, 2015. These options were due to expire on February 3, 2025. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:32 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionIncentive Stock Option · Derivative | 4,812 | $0.00 Strike: $32.99 | $0.00 |
DisclosureSEC source: 0000914475-25-000004 · wk-form4_1737149514.xml · derivative · entry 5 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,812 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted February 3, 2015 and vested in 48 equal monthly installments beginning on March 3, 2015. These options were due to expire on February 3, 2025. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:32 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 60,188 | $141.50 | $8,516,656.17 |
DisclosureSEC source: 0000914475-25-000004 · wk-form4_1737149514.xml · nonDerivative · entry 4 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,392 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.53 to $142.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes an aggregate of 226 shares purchased on February 29, 2024, from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:32 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 60,188 | $32.99 | $1,985,602.12 |
DisclosureSEC source: 0000914475-25-000004 · wk-form4_1737149514.xml · nonDerivative · entry 3 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 195,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:32 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | SaleCommon Stock | 4,812 | $141.50 | $680,893.67 |
DisclosureSEC source: 0000914475-25-000004 · wk-form4_1737149514.xml · nonDerivative · entry 2 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,392 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.53 to $142.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:32 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 4,812 | $32.99 | $158,747.88 |
DisclosureSEC source: 0000914475-25-000004 · wk-form4_1737149514.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2024 Filed Nov 1, 2024 23:52 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 13,344 | $0.00 Strike: $122.21 | $0.00 |
DisclosureSEC source: 0000914475-24-000216 · wk-form4_1730505118.xml · derivative · entry 2 Gano Kyle · CIK 0001567160 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,344 Underlying: Common Stock · 13,344 shares Expires 2034-11-01 F3 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on December 1, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.